EN
中文 EN
Newsroom
Company News
Media Report
Company News
More
2026-03-31
CanSinoBIO's CEO Xuefeng Yu on Bloomberg: Building Long-Term Competitiveness Through Innovation and Global Vision
CanSinoBIO Signs PCV13i LOI with Pakistani Partner to Expand Vaccine Collaboration in South Asia
2026-07-21
CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years
2026-07-19
CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach
2026-06-25
CanSinoBIO Holds 2025 Annual General Meeting of Shareholders
2026-06-10
CanSinoBIO Advances Pneumococcal Disease Prevention Strategy with Initiation of Phase I/II Trial for PCV24
2026-05-25
Media Report
More
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Time：2025-03-28
More
CanSinoBIO to Showcase China’s Vaccine Innovation at 2025 World Government Summit in Dubai
Time：2025-02-14
More
CanSinoBIO Secures Further Funding from the Bill & Melinda Gates Foundation
Time：2024-10-09Source：ACN Newswire
More